^Yevich JP; New JS; Smith DW; et al. (1986). „Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents”.Journal of Medicinal Chemistry.29 (3): 359—69.PMID2869146.doi:10.1021/jm00153a010.
^Jain AK, Kelwala S, Moore N, Gershon S (1987). „A controlled clinical trial of tiaspirone in schizophrenia”.International Clinical Psychopharmacology.2 (2): 129—33.PMID2885367.doi:10.1097/00004850-198704000-00006.
^Moore NC, Meyendorff E, Yeragani V, LeWitt PA, Gershon S (1987). „Tiaspirone in schizophrenia”.Journal of Clinical Psychopharmacology.7 (2): 98—101.PMID3294920.
^Borison RL, Sinha D, Haverstock S, McLarnon MC, Diamond BI (1989). „Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double-blind, placebo-controlled trial”.Psychopharmacology Bulletin.25 (2): 190—3.PMID2574893.
^абIshizumi K, Kojima A, Antoku F, Saji I, Yoshigi M (1995). „Succinimide derivatives. II. Synthesis and antipsychotic activity of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis- cyclohexanedicarboximide (SM-9018) and related compounds”.Chemical & Pharmaceutical Bulletin.43 (12): 2139—51.PMID8582016.doi:10.1248/cpb.43.2139.
^Sumiyoshi T; Suzuki K; Sakamoto H; et al. (1995). „Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy”.Neuropsychopharmacology.12 (1): 57—64.PMID7766287.doi:10.1016/0893-133X(94)00064-7.
^Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY (1995). „D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs”.Psychopharmacology.120 (3): 365—8.PMID8524985.doi:10.1007/BF02311185.
^Weiner DM; Burstein ES; Nash N; et al. (2001). „5-hydroxytryptamine2A receptor inverse agonists as antipsychotics”.The Journal of Pharmacology and Experimental Therapeutics.299 (1): 268—76.PMID11561089.
^Herrick-Davis K, Grinde E, Teitler M (2000). „Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors”.The Journal of Pharmacology and Experimental Therapeutics.295 (1): 226—32.PMID10991983.
^Rauly-Lestienne I, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Cussac D (2007). „Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties”.Naunyn-Schmiedeberg's Archives of Pharmacology.376 (1–2): 93—105.PMID17786406.doi:10.1007/s00210-007-0182-6. ISBN.
Да
